Muscle paralysis by rocuronium during halothane, enflurane, isoflurane, and total intravenous anesthesia. 1993

B Oris, and J F Crul, and E Vandermeersch, and H Van Aken, and J Van Egmond, and M B Sabbe
Department of Anesthesiology, Katholieke Universiteit Leuven, Belgium.

We determined the dose-response relationship, the onset time, the duration, and the recovery time of a rocuronium neuromuscular block under four anesthesia techniques. Patients were equally randomized to four different groups (n = 20) receiving 0.5%-1% halothane, 1.5%-2% enflurane, 1.2%-1.8% isoflurane end-tidal concentration in 34%/66% O2/N2O, or 6.0 mg.kg-1 x h-1 propofol without N2O for anesthesia and alfentanil for analgesia. Strength of thumb adduction in response to single and train-of-four stimulation of the ulnar nerve was quantitated. Rocuronium 0.15, 0.2, 0.25, and 0.3 mg/kg were given intravenously. When maximal depression of twitch tension occurred, supplemental doses up to a total of 0.5 mg/kg were given. If required, additional doses of 0.15 mg/kg were given at 25% recovery of control twitch tension. Standard hemodynamics, end-tidal CO2, and anesthetic gas concentrations were monitored continuously. The mean ED50 (SD) was 0.133 (+/- 0.009) mg/kg for the halothane group, 0.118 (+/- 0.012) mg/kg for the enflurane group, 0.069 (+/- 0.026) mg/kg for the isoflurane group, and 0.167 (+/- 0.007) mg/kg for the total intravenous anesthesia (TIVA) group, respectively. There was a statistically significant difference between the halothane and TIVA, and between the enflurane and TIVA groups (P < 0.05). Rocuronium has a short onset time and an intermediate duration of action. The neuromuscular blocking potency and pharmacodynamic profile are moderately influenced by volatile anesthetics.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009126 Muscle Relaxation That phase of a muscle twitch during which a muscle returns to a resting position. Muscle Relaxations,Relaxation, Muscle,Relaxations, Muscle
D003473 Neuromuscular Nondepolarizing Agents Drugs that interrupt transmission at the skeletal neuromuscular junction without causing depolarization of the motor end plate. They prevent acetylcholine from triggering muscle contraction and are used as muscle relaxants during electroshock treatments, in convulsive states, and as anesthesia adjuvants. Curare-Like Agents,Curariform Drugs,Muscle Relaxants, Non-Depolarizing,Neuromuscular Blocking Agents, Competitive,Nondepolarizing Blockers,Agents, Curare-Like,Agents, Neuromuscular Nondepolarizing,Blockers, Nondepolarizing,Curare Like Agents,Drugs, Curariform,Muscle Relaxants, Non Depolarizing,Non-Depolarizing Muscle Relaxants,Nondepolarizing Agents, Neuromuscular
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D004347 Drug Interactions The action of a drug that may affect the activity, metabolism, or toxicity of another drug. Drug Interaction,Interaction, Drug,Interactions, Drug
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000077123 Rocuronium An androstanol non-depolarizing neuromuscular blocking agent. It has a mono-quaternary structure and is a weaker nicotinic antagonist than PANCURONIUM. Androstane-3,17-diol, 2-(4-morpholinyl)-16-(1-(2-propen-1-yl)-1-pyrrolidiniumyl)-, 17-acetate, (2beta,3alpha,5alpha,16beta,17beta)-,1-(17-(Acetoyl)-3-hydroxy-2-(4-morpholinyl)androstan-16-yl)-1-(2-propenyl)pyrrolidinium,Esmeron,Esmerone,ORG 9426,ORG-9426,Pyrrolidinium, 1-((2beta,3alpha,5alpha,16beta,17beta)-17-(acetyloxy)-3-hydroxy-2-(4-morpholinyl)androstan-16-yl)-1-(2-propenyl)-, bromide,Rocuronium Bromide,Zemuron,ORG9426
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

B Oris, and J F Crul, and E Vandermeersch, and H Van Aken, and J Van Egmond, and M B Sabbe
May 1987, Anesthesiology,
B Oris, and J F Crul, and E Vandermeersch, and H Van Aken, and J Van Egmond, and M B Sabbe
October 1983, Anesthesiology,
B Oris, and J F Crul, and E Vandermeersch, and H Van Aken, and J Van Egmond, and M B Sabbe
October 1998, Anesthesia and analgesia,
B Oris, and J F Crul, and E Vandermeersch, and H Van Aken, and J Van Egmond, and M B Sabbe
February 1984, Anesthesiology,
B Oris, and J F Crul, and E Vandermeersch, and H Van Aken, and J Van Egmond, and M B Sabbe
April 1993, Anesthesiology,
B Oris, and J F Crul, and E Vandermeersch, and H Van Aken, and J Van Egmond, and M B Sabbe
January 1977, Anesthesiology,
B Oris, and J F Crul, and E Vandermeersch, and H Van Aken, and J Van Egmond, and M B Sabbe
December 1987, Anesthesia and analgesia,
B Oris, and J F Crul, and E Vandermeersch, and H Van Aken, and J Van Egmond, and M B Sabbe
August 1992, Masui. The Japanese journal of anesthesiology,
B Oris, and J F Crul, and E Vandermeersch, and H Van Aken, and J Van Egmond, and M B Sabbe
January 1982, Anesthesiology,
B Oris, and J F Crul, and E Vandermeersch, and H Van Aken, and J Van Egmond, and M B Sabbe
July 1981, Anesthesia and analgesia,
Copied contents to your clipboard!